(S)-4-(Difluoromethyl)-5-(4-(3-methylmorpholino)-6-morpholino-1,3,5-triazin-2-yl)pyridin-2-amine (PQR530), a Potent, Orally Bioavailable, and Brain-Penetrable Dual Inhibitor of Class I PI3K and mTOR Kinase.
Rageot, D., Bohnacker, T., Keles, E., McPhail, J.A., Hoffmann, R.M., Melone, A., Borsari, C., Sriramaratnam, R., Sele, A.M., Beaufils, F., Hebeisen, P., Fabbro, D., Hillmann, P., Burke, J.E., Wymann, M.P.(2019) J Med Chem 62: 6241-6261
- PubMed: 31244112 
- DOI: 10.1021/acs.jmedchem.9b00525
- Primary Citation of Related Structures:  
6OAC - PubMed Abstract: 
The phosphoinositide 3-kinase (PI3K)/mechanistic target of rapamycin (mTOR) pathway is frequently overactivated in cancer, and drives cell growth, proliferation, survival, and metastasis. Here, we report a structure-activity relationship study, which led to the discovery of a drug-like adenosine 5'-triphosphate-site PI3K/mTOR kinase inhibitor: ( S )-4-(difluoromethyl)-5-(4-(3-methylmorpholino)-6-morpholino-1,3,5-triazin-2-yl)pyridin-2-amine (PQR530, compound 6 ), which qualifies as a clinical candidate due to its potency and specificity for PI3K and mTOR kinases, and its pharmacokinetic properties, including brain penetration ...